December 15th, 2015

Stock Update: Biogen Idec Inc (NASDAQ:BIIB) – Biogen Presents New Anti-LINGO-1 Phase 2 Acute Optic Neuritis Data Demonstrating Neurological Repair

[Business Wire] – Today, Biogen announced detailed results from the Phase 2 RENEW study of anti-LINGO-1 in acute optic neuritis – the first clinical study to demonstrate remyelination following an inflammatory injury in . . . → Read More: Stock Update: Biogen Idec Inc (NASDAQ:BIIB) – Biogen Presents New Anti-LINGO-1 Phase 2 Acute Optic Neuritis Data Demonstrating Neurological Repair Similar Articles: Company Update: Biogen Idec Inc (NASDAQ:BIIB) – Biogen Data at AAN Annual Meeting Underscore Commitment to Advancing Patient Care in Neurology Company Update (NASDAQ:BIIB): Here’s who’s getting rich off of Biogen Idec’s success Stock Update: Biogen Idec Inc (NASDAQ:BIIB) – Biogen experimental drug shows evidence of optic nerve repair
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.